Norway, Aug. 5 -- Thor Medical ASA, a leading emerging supplier of alpha-emitters for next-generation precision cancer treatment, has expanded its strategic master supply agreement with AdvanCell, a leading radiopharmaceutical company with an extensive clinical development program for innovative cancer therapies.The new agreement effectively increases the supply of Thorium-228 to AdvanCell by 50% and the total purchasing commitment from NOK 100 million to NOK 150 million over five years. The increase is enabled by the decision to expand the capacity at the AlphaOne plant under construction by up to 40%, which will be financed with proceeds from the capital raise executed by Thor Medical earlier in June. Thor Medical and AdvanCell first ente...